kartogenin and Pain

kartogenin has been researched along with Pain* in 2 studies

Other Studies

2 other study(ies) available for kartogenin and Pain

ArticleYear
Magnetic nanocarriers as a therapeutic drug delivery strategy for promoting pain-related motor functions in a rat model of cartilage transplantation.
    Journal of materials science. Materials in medicine, 2021, Mar-31, Volume: 32, Issue:4

    Cartilage is an avascular tissue with low cellularity and insufficient self-repair response. In clinical practice, a large articular cartilage defect is usually fixed by cartilage transplantation. Importantly, the fast repair process has been demanded postoperatively in the area between the host cartilage and the transplanted cartilage. In the past few years, magnetic nanoparticles have drawn great attention due to their biocompatible, biodegradable, and nontoxic properties. In addition, the nanoparticles can easily pass through the cell plasma membrane and increase the cellular uptake efficiency. Here, a therapeutic drug delivery strategy was proposed for cartilage repair. The prepared kartogenin (KGN)-conjugated magnetic nanocarriers (KGN@NCs) promoted the viability of chondrocytes in vitro. In a rat model of cartilage transplantation, intra-articularly delivered KGN@NCs generated cartilage with a flat surface and a high level of aggrecan in vivo. Notably, KGN@NCs were also capable of improving the pain-related motor functions. They promoted the motor functional parameters including the print area and intensity to restore to a normal level compared with the single KGN. Therefore, these therapeutic drug nanocarriers provided the potential for cartilage repair.

    Topics: Aggrecans; Anilides; Animals; Cartilage, Articular; Chondrocytes; Chondrogenesis; Drug Carriers; Drug Delivery Systems; Ferric Compounds; Gait; In Vitro Techniques; Inflammation; Injections, Intra-Articular; Magnetite Nanoparticles; Nanomedicine; Pain; Pain Management; Phthalic Acids; Rats

2021
Kartogenin inhibits pain behavior, chondrocyte inflammation, and attenuates osteoarthritis progression in mice through induction of IL-10.
    Scientific reports, 2018, 09-14, Volume: 8, Issue:1

    Osteoarthritis (OA) is a major degenerative joint condition that causes articular cartilage destruction. It was recently found that enhancement of chondroclasts and suppression in Treg cell differentiation are involved in the pathogenesis of OA. Kartogenin (KGN) is a small drug-like molecule that induces chondrogenesis in mesenchymal stem cells (MSCs). This study aimed to identify whether KGN can enhance severe pain behavior and improve cartilage repair in OA rat model. Induction of OA model was loaded by IA-injection of MIA. In the OA rat model, treatment an intra-articular injection of KGN. Pain levels were evaluated by analyzing PWL and PWT response in animals. Histological analysis and micro-CT images of femurs were used to analyze cartilage destruction. Gene expression was measured by real-time PCR. Immunohistochemistry was analyzed to detect protein expression. KGN injection significantly decreased pain severity and joint destruction in the MIA-induced OA model. KGN also increased mRNA levels of the anti-inflammatory cytokine IL-10 in OA patients' chondrocytes stimulated by IL-1β. Decreased chondroclast expression, and increased Treg cell expression. KGN revealed therapeutic activity with the potential to reduce pain and improve cartilage destruction. Thus, KGN could be a therapeutic molecule for OA that inhibits cartilage damage.

    Topics: Anilides; Animals; Cartilage; Cartilage, Articular; Celecoxib; Chondrocytes; Chondrogenesis; Cytokines; Disease Models, Animal; Humans; Inflammation; Injections, Intra-Articular; Interleukin-10; Interleukin-1beta; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred DBA; Mice, Knockout; Osteoarthritis; Pain; Pain Management; Phthalic Acids; Rats; Rats, Wistar

2018